Form 8-K - Current report:
SEC Accession No. 0001213900-24-102134
Filing Date
2024-11-25
Accepted
2024-11-25 16:00:32
Documents
14
Period of Report
2024-11-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0222513-8k_estrella.htm   iXBRL 8-K 35574
  Complete submission text file 0001213900-24-102134.txt   258089

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE esla-20241125.xsd EX-101.SCH 3863
3 XBRL DEFINITION FILE esla-20241125_def.xml EX-101.DEF 26753
4 XBRL LABEL FILE esla-20241125_lab.xml EX-101.LAB 36958
5 XBRL PRESENTATION FILE esla-20241125_pre.xml EX-101.PRE 25377
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0222513-8k_estrella_htm.xml XML 6079
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40608 | Film No.: 241495782
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)